It sounds like the plot of a pulp adventure novel: a man lets himself be bitten by some of the most lethal snakes on Earth-hundreds of times over two decades-not for spectacle, but to turn his own body into a living laboratory. Yet that is precisely what Tim Friede, a self-taught venom expert from Wisconsin, did. His extreme self-immunization has now given science something unprecedented: human-derived antibodies that form the backbone of a broad-spectrum antivenom, potentially capable of neutralizing the neurotoxins of dozens of deadly snakes.
Snakebite envenoming is one of the world’s deadliest neglected tropical diseases; it kills more than 100,000 people annually and leaves hundreds of thousands more permanently disabled, mostly in rural areas of South Asia, Sub-Saharan Africa, and Latin America. Current antivenoms are still based on a century-old approach: immunizing horses or sheep with venom and harvesting their antibodies. These sera tend to be species-specific, can trigger dangerous immune reactions, and require cold-chain storage, making them challenging to deploy in the very regions where they are most needed.
Friede’s blood offered a radically different starting point. Over nearly 20 years, he endured more than 200 venomous bites and over 850 controlled venom injections from species including black mambas, king cobras, taipans, and kraits. This relentless exposure trained his immune system to produce “broadly neutralizing antibodies” (bnAbs) that target conserved structural features of snake neurotoxins-regions so essential to the toxins’ function that they remain nearly unchanged across species. In molecular terms, many of these toxins are three-finger α-neurotoxins (3FTXs) that bind to nicotinic acetylcholine receptors (nAChRs) at neuromuscular junctions, causing paralysis and respiratory failure. Friede’s antibodies evolved to mimic the receptor’s own binding loops, blocking the toxins before they can attach.
Researchers at Centivax and Columbia University, headed by Jacob Glanville and Peter Kwong, respectively, isolated two standout antibodies from Friede’s memory B cells: LNX-D09, targeting long-chain 3FTXs, and SNX-B03, which binds short-chain 3FTXs. Crystallographic studies via X-ray crystallography showed that LNX-D09’s CDR-H3 loop closely imitates the “loop C” of nAChR, making it a perfect molecular decoy for the toxin. SNX-B03 uses a similar receptor-mimicking strategy for its targets.
But neurotoxins are only part of the venom arsenal. Many elapids, including taipans and tiger snakes, also depend on phospholipase A₂ enzymes, which wreak havoc on cell membranes, lead to muscle necrosis, and enhance the activity of other toxins. To counter this, the team added varespladib, a potent small-molecule PLA₂ inhibitor already shown to block a broad range of venom PLA₂s. The resulting three-component cocktail-LNX-D09, SNX-B03, and varespladib-was pitted against the World Health Organization’s 19 most medically important elapid species. In preclinical mouse models, it provided complete protection against 13 species and partial protection against six more, including notoriously lethal snakes such as the inland taipan and common krait.
The breadth of this protection is “unparalleled,” Glanville says, because it targets the dominant toxin classes in most elapid venoms. Also, because the antibodies are of human origin, there is no risk of serum sickness and anaphylaxis associated with animal-derived antivenoms. Recombinant production offers the potential of consistent quality, and storage and transport may also be easier.
The implications are enormous from a global health perspective: snakebite mortality is highest where antivenom supply chains are weakest, and where species diversity makes stocking all necessary serums impractical. A universal or near-universal antivenom could transform emergency care, especially in rural clinics where the biting species is unknown. Additional antibodies-such as those targeting viperid metalloproteinases (SVMPs) or cytotoxic PLA₂s-could be incorporated to expand coverage beyond elapids because of the modular design of this therapy.
Further work ahead will involve the cocktail being put to the test in real-life settings, first in veterinary cases in Australia, where the elapids are the only venomous snakes present and bites to dogs are frequent. Researchers also are refining the formulation to determine the minimum number of antibodies required to get the best coverage and whether adding a fourth component could achieve full protection across all tested species.
Friede’s radical path to immunity is not one to be emulated; both he and the scientists emphasize that his case is “once-in-history” and should not encourage copycats. But his unusual biology has opened a door that decades of conventional research had left ajar. By uniting structural immunology, toxin biochemistry, and recombinant drug design, his antibodies may help end one of humanity’s oldest and deadliest natural threats.
